Will HARMONi-3 squamous interim PFS analysis report statistically significant results by Q3 2026?

Four prior China-based Phase III trials showed consistent PFS benefit with ivonescimab. The dual PD-1/VEGF mechanism has strong biological rationale. Squamous NSCLC responded well in prior data. However, US population may differ and interim analysis may not cross the pre-specified efficacy boundary even with a positive trend. Geographic generalizability is the key uncertainty.

The pre-specified interim analysis adds a statistical hurdle — the efficacy boundary for interim looks is typically more stringent than final analysis. Even if the drug works, the interim may not reach the stopping boundary. Adjusting downward from base case for the interim analysis statistical penalty.

Management proactively added the interim PFS analysis to the protocol — suggesting they have internal monitoring data showing favorable trends. Combined with enrollment completion, the event rate is likely sufficient. The biological mechanism is population-independent, supporting geographic generalizability. Weighting management's protocol amendment as a positive signal.

The consistency of PFS benefit across four Phase III trials is the strongest evidence. Squamous NSCLC is a well-characterized population. The question is whether the US/global population replicates China results. Slight haircut for geographic uncertainty but the mechanism of action supports generalizability.

More cautious view. The question is specifically about statistically significant results at an interim analysis. Interim analyses have higher bars (alpha spending). The sample size for the squamous cohort alone may be smaller than the full trial. China-to-global translation has a mixed track record in oncology. Setting probability modestly above 50%.

If management added an interim analysis to the protocol, they likely have unblinded monitoring data showing efficacy. Companies do not typically add interim looks unless data monitoring committees signal favorable trends. This is a strong positive indicator. The prior data consistency further supports positive results.

Four positive Phase III trials give strong prior. Enrollment complete means events are accruing. Management added interim analysis proactively. Slight discount for US population and interim statistical hurdle.

Oncology drug development has a high failure rate even with positive earlier-phase data. Geographic translation is uncertain. The interim analysis bar is high. Moderate probability weighted by strong priors.

Weight of evidence favors positive PFS. Dual mechanism is robust. Management behavior signals confidence. Consensus leans positive but with meaningful uncertainty.